The World Health Organization’s Strategic Advisory Group of Experts on Immunization meets today in an extraordinary session, scheduled for 14:00 to 17:00 UTC. The word “extraordinary” is the newsworthy part: SAGE has a fixed calendar, and sessions outside it are called when something will not wait.

What SAGE is

SAGE is the WHO’s principal advisory group on vaccines and immunisation. It is not a regulator and it does not license products — that is done by national medicines agencies. What it does is issue recommendations on how vaccines should be used: who should receive them, in what order, at what interval, and under what circumstances.

Those recommendations carry weight out of proportion to their formal status. Many countries write national immunisation policy directly from them. Procurement bodies and funders use them to decide what to buy and for whom. In practice, a SAGE position determines where limited doses go.

Why an extraordinary session is a signal

Ordinary SAGE meetings are scheduled far ahead, run over several days, and work through a long agenda. An extraordinary session compressed into three hours has a different character: a narrow question requiring a decision sooner than the next scheduled meeting allows.

Historically, sessions of this kind have been convened for things like allocating a constrained vaccine supply during an outbreak, or advising on the use of a product that has not completed the usual approval route. We should be careful here: WHO has not published the agenda, and it would be wrong to state what will be discussed. The timing is suggestive, not conclusive.

The context it sits in

What is not speculative is the situation around it. The Ebola outbreak in the Democratic Republic of the Congo and Uganda has passed 4,900 confirmed cases and 2,300 deaths, and the species involved — Bundibugyo — has no licensed vaccine, as we set out in our report on the outbreak. Candidate vaccines are being tested. The WHO Director-General convened a cross-border consultative meeting on the same virus on 17 August, two days before this session.

WHO also has a separate technical advisory group on candidate vaccine prioritisation, which met earlier this month. The machinery for deciding which unlicensed candidate gets used, and in whom, exists and has been active.

The decision that would matter

Whatever prompts this particular meeting, the recurring hard question in outbreak immunisation is worth naming, because it will come up again.

When a vaccine exists only as a candidate, deploying it during an outbreak means giving an unlicensed product to people in an emergency. Doing so can save lives and can also generate the evidence needed for licensure. It also raises consent questions in populations with limited access to information, and risks damaging trust badly if something goes wrong — trust that contact tracing depends on entirely.

Public health ethicists have argued both sides of this for a decade, and the arguments are not frivolous on either side. Whatever SAGE concludes today, it will publish its recommendations afterwards, and those documents are the thing to read rather than the coverage of the meeting.

Sources

• World Health Organization — meeting calendar, extraordinary SAGE session, 19 August 2026
• WHO — Ebola outbreak, DRC 2026, and vaccine status